WHO IS MONAL
Monal Therapeutics is a development stage biotechnology company dedicated to transforming oncology with innovative solutions based on cutting-edge science. Monal has created targeted drug complexes specifically aimed at the key PROTEIN in cancer cells – Cytochrome-C, the engine of the apoptosis reaction.
Monal’s bioengineered, intelligent, non-toxic drug complexes target cancer at its core by disrupting dysfunctional mitochondrial dynamics, halting cancer growth, preventing metastasis, and enhancing the patient’s immune response.
